New Delhi: Evidence in a case against Ranbaxy is likely to be furnished in the Supreme Court on Monday. Earlier in August, the Supreme Court while replying to a petition seeking cancellation of Ranbaxy's manufacturing licence had said that the petitioner can file the documents to prove that the company sold adulterated drugs.
The Supreme Court had on June 25 dismissed a PIL which had alleged that Ranbaxy manufactured and sold adulterated drugs. The court in its order said that there is no evidence to show that the pharma giant manufactured substandard drugs. The apex court also said that the petitioner failed to bring in evidence against Ranbaxy.
The PIL was filed against Ranbaxy for allegedly manufacturing and selling of the adulterated drug. The petitioner cited the pharma giant's case in the US where Ranbaxy USA admitted to selling substandard and adulterated drugs. The pharma giant was asked to pay a fine of 500 million dollars
Comments
0 comment